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In human microbiome research, reproducibility is
crucial because the microbial ecosystem is heavily
influenced by environmental factors and highly vari-
able between individuals. This poses challenges when
designing such studies and recruiting suitable subjects.
Furthermore, the employed methodology of data
acquisition and analysis can be highly customized, and
differences in the work flow may introduce biases and
hamper comparisons between studies.
In the last 2 years, the gut microbiome has gained
increasing attention in the Parkinson’s disease research
community because of its possible implication in the
prominent gastrointestinal disturbances frequently pre-
sent from the earliest stages of PD and the ascension
hypothesis of PD-related neuropathology.1 So far, 9
original publications have reported gut microbiota
alterations in PD.2-10 As could be expected, the subject
selection criteria, laboratory protocols, and bioinfor-
matical and statistical pipelines differed considerably
between studies. Sample size ranged from 38 to 327
subjects. Most studies used 16S ribosomal RNA
amplicon sequencing to assess the community struc-
ture of the gut microbiota, whereas 2 studies relied on
qPCR analysis of preselected bacterial taxa. These
approaches are relatively cost effective and allow a
description of differences in the relative abundances of
bacterial taxa between study groups (ie, the commu-
nity structure).
Despite the above-mentioned limitations and con-
siderable differences in their methodology and results,
it is encouraging that the abovementioned studies
showed clear overlaps with respect to the bacterial
taxa differentially abundant between PD patients and
control subjects. Increased abundance of Akkerman-
sia2,3,5-7 and Lactobacillus2,4,6,8,9 and decreased abun-
dance of Prevotella2,4,5,7,8 in PD subjects were reported
in 5 studies. Other reproducible findings were reduced
abundance of Faecalibacterium5,6,8,10 (4 studies) and
Blautia3,6,10 (3 studies) and increased abundance of Bifi-
dobacterium5,6,8 (3 studies) in PD.
So by now, that the gut microbial community struc-
tures of PD patients and controls differ seems to be
reasonably well established, with several bacterial gen-
era showing consistent abundance alterations in multi-
ple studies. However, it was not known whether these
alterations precede the development of PD or whether
they are rather a consequence of a dysfunctional gut
associated with PD.
In this issue of Movement Disorders, Heintz-
Buschart et al add an important piece of evidence to
the field by demonstrating that indeed gut microbiome
alterations may precede the motor symptoms of PD.11
In addition to patients with established PD, they stud-
ied a group of subjects suffering from a well-defined
prodromal syndrome of PD, namely, rapid eye move-
ment sleep behavior disorder (RBD). Because RBD is
associated with an up to 90% risk of developing a
neurodegenerative disorder later on (mostly synuclei-
nopathies), it is considered a promising criterion for
selection of patients for premotor trials of disease-
modifying treatments.12
In their study, Heintz-Buschart et al employed state-
of-the-art analytical pipelines to assess microbiome
community structure in nasal and fecal samples and
aimed to account for potential confounders such as
constipation and medications.11 The rationale for the
analysis of nasal microbiota was that, like the gastro-
intestinal tract, the nasal cavity has been suggested to
constitute a port of entry for a possible pathogenic
agent.1 For the first time, in this study, nasal microbial
communities were directly compared with fecal com-
munities. As has been previously described, the nasal
bacterial community was sparse and showed high
interindividual variation.11,13 Operational taxonomic
units (OTUs) common to the nasal and gastrointesti-
nal microbiota were found, likely attributable to nasal
discharge being swallowed. However, none of these
OTUs differed significantly between study groups.
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Regarding taxa that were differentially distributed
between PD patients and controls, effects of sex and
medications seemed to explain more of the observed
differences than PD itself. Therefore, the authors agree
with a previous study that the biomarker potential of
nasal microbiota for PD seems limited.11,13
The analysis of fecal microbiota at the genus level
showed an increased abundance of Akkermansia in
the feces of PD patients, in line with several previous
studies.2,3,5-7,11 Also, Clostridium XlVb and Anaero-
truncus were enriched in PD subjects, but showing
also increased abundance in RBD subjects. However,
in contrast to Akkermansia, these were not confirmed
by the more stringent Analysis of composition of
microbiomes (ANCOM) analysis. Eight further genera
showed altered abundance in RBD. Of these, only
decreased abundance of Prevotella was confirmed by
ANCOM. On the OTU level, OTUs assigned to
Akkermansia (increased in PD), Prevotella, and Clos-
tridiales (both decreased in PD), and Flavonifractor
(increased in PD and RBD) were confirmed by
ANCOM. In addition to the Flavonifractor OTU, 9
other OTUs showed significant differences in abun-
dance in the same direction in PD and RBD
subjects versus controls, but were not confirmed by
ANCOM: OTUs assigned to Prevotellaceae, Olsenella,
Bacteroides, Ruminococcaceae, Sutterella, and an a-
proteobacterium were decreased in PD and RBD,
whereas OTUs assigned to Anaerotruncus and Clos-
tridium XlVa were increased in PD and RBD.
So the most robust findings from this complex anal-
ysis seem to be an increased abundance of Akkerman-
sia in PD and a decreased abundance of Prevotella in
PD (1 OTU) and RBD (genus), together with dec-
reased abundance of a Clostridiales OTU in PD and
an increased abundance of a Flavonifractor OTU in
PD and RBD. So not only do these results support
previous findings regarding altered abundance of
Akkermansia and Prevotella in PD, but for the first
time it has been shown that regarding Prevotella such
alterations may already be detected in the prodromal
period.2-8 The relevance of the Clostridiales and Flavo-
nifractor OTUs, which showed comparably low mean
abundance compared with the previous ones remains
to be established.
The pure comparison between patient groups,
although the cornerstone of the analysis, can be influ-
enced by other, possibly unknown confounding factors
that are differentially distributed between the study
groups. Associations between bacterial abundance and
clinical symptoms of the PD spectrum can add plausi-
bility to these findings and can support, although not
prove, causal connections. Of the most robustly
altered genera in PD, Akkermansia was negatively
associated with nonmotor symptom burden, as mea-
sured by the MDS UPDRS I.11 Several other genera
and OTUs including Anaerotruncus and Clostridium
XIVb showed associations with motor and nonmotor
symptoms.11 This supports previous reports of connec-
tions between motor and nonmotor symptoms and gut
microbiota.2,14
Virtually all RBD patients will go on to develop a syn-
ucleinopathy.12 Thus, although not formally a longitudi-
nal study, this important article gives some insight into
the likely time course of microbiome changes in PD. It
suggests that a decreased abundance of Prevotella pre-
cedes the motor phase, at least in PD patients suffering
from premotor RBD. Because RBD patients were drug
naive in relation to PD medications, this study strongly
suggests that reduced Prevotella abundance is not
explained by PD medications, a question that was diffi-
cult to assess in previous case-control studies of medi-
cated patients. Furthermore, these changes do not seem
to be a consequence of the development of overt motor
deficits and corresponding dopaminergic denervation.
The article by Heintz-Buschart et al is an important
step toward a better understanding of the role of
microbiota in PD. That microbiome alterations could
already be detected in the premotor period in a sub-
group of PD patients makes gut microbiota appear as
an even more promising PD biomarker than before.
Now it seems possible that future therapeutic trials
aimed at microbiome modulation may already be
applied in premotor patients.
However, one major question still remains unan-
swered, and that is the specificity of these exciting find-
ings. As in all previous studies on microbiota and PD,
constipation is an important potential confounder.
Although most studies, including the one by Heintz-
Buschart et al, tried to assess constipation using ques-
tionnaires and accounted for it in the analysis, this
problem has so far not been sufficiently addressed. The
main problem is that in PD objective colonic dysfunc-
tion seems to be far more prevalent than patient-
reported constipation symptoms.15 No specific consti-
pation questionnaire has been formally validated in PD
patients using objective measurements of gut function
as a gold standard. As in this study, a significant propor-
tion of RBD patients also reported constipation, the
same limitation also applies to the RBD-related find-
ings. Gut microbiome composition, in particular abun-
dance of Akkermansia and Prevotella, clearly correlates
with gastrointestinal symptoms, transit time and stool
consistency.14,16 Therefore, it is not clear whether these
changes are merely a consequence of PD-related gut
dysfunction or whether they are a contributing factor.
However, because constipation itself is associated with
an increased risk of PD, this knowledge gap does not
reduce the importance of these findings for a better
understanding of PD pathogenesis.
Based on the attributed functions of the bacterial
taxa now reproducibly associated with PD, gut
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mucosal integrity, short-chain fatty acids, and inflam-
mation could be important pathways linking micro-
biota and PD. However, depending on environmental
and intrinsic factors, bacterial taxa can contribute in
different ways to the ecosystem of the gut. Therefore,
differences in the taxonomic composition of micro-
biota do not necessarily reflect functional differ-
ences.17 Predictions of the functional potential can be
calculated based on microbial abundance and data on
microbial genomic content from public databases.
However, these predictions may be inaccurate as they,
for example, do not account for microbes without
sequenced genomes.11
As Heintz-Buschart et al concluded, only metage-
nomic analyses based on shotgun sequencing can truly
inform the functional capacity of the microbiota.11
Furthermore, metagenomics allows the extension of
the scope of analysis to other microbes, but for these
purposes it has so far only been used in 1 PD study.7
Multiomic approaches studying the activity of the
microbiome and its interactions with the genome and
immune system of the host will hopefully help a better
understanding and treatment PD in the future.
Now that we have been introduced to the prodro-
mal microbiome, it is time to figure out what it is
doing to our patients.
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